ACC 2023: Late-Breaking Science Video Collection

Published: 06 March 2023

  • Views:

    Views Icon 6076
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Our regular review series View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provides a critical analysis of the late-breaking and featured science results and spotlights impactful data. 

 

For a deeper look into the key clinical trial data revealed at ACC 23, Dr Harriette Van Spall (McMaster University, Hamilton, CA) interviews the principal investigators in her regular Late-Breaker Discussion Series

 

For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research. 

More from this programme

Part 3

View from the Thoraxcenter

In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at ACC 2023. 

About the episode

ACC.23/WCC - We are joined by Dr Paul Ridker (Brigham and Women’s Hospital, US) to discuss the findings from a collaborative analysis of 31,197 patients to assess inflammatory risk in statin-treated patients. The PROMINENT, REDUCE-IT and STRENGTH trials were each large contemporary trials which implemented guideline-directed medical therapy, the findings of which were pooled in this study. The aim of this study was to investigate the predictor of future cardiovascular events, cardiovascular deaths, and all-cause mortality. 

Results suggest a small gradient of risk with LDL cholesterol but are higher in patients with elevated high-sensitivity C-reactive protein. 

Questions: 

  1. What is the reasoning behind this study?
  2. What was the patient population and study design?
  3. What are the main findings?
  4. How should these findings impact clinical practice and patient outcomes?
  5. What are the knowledge gaps, and what further study is required?

Recorded on-site at ACC 2023, New Orleans.

Faculty Biographies

Paul M Ridker

Paul M Ridker

Senior Physician, Brigham and Women's Hospital Eugene Braunwald Professor of Medicine, Harvard Medical School

Dr Paul M Ridker is director of the Center for Cardiovascular Disease Prevention, a translational research unit at Brigham and Women’s Hospital (BWH). A cardiovascular medicine specialist, he is also the Eugene Braunwald Professor of Medicine at Harvard School of Medicine (HMS).

Dr Ridker received his medical degree from HMS. He then completed an internal medicine residency and a cardiology fellowship at BWH. He has authored over 500 peer-reviewed publications, 150 reviews and book chapters, and five textbooks related to cardiovascular medicine. Dr Ridker’s primary research focus has involved inflammatory mediators of heart disease and the molecular and genetic epidemiology of hemostasis and thrombosis, with particular interests in biomarkers for coronary disease, “predictive” medicine, and the underlying causes and prevention of atherosclerotic disease.

View full profile

Comments

You must be to comment. If you are not registered, you can register here.